Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b Single Dose Clinical Trial of a Novel Long-Acting Bispecific Antibody in People With HIV to Inform Development for HIV Pre- and Post-Exposure Prophylaxis

Next Previous
Search
Trial Profile

Phase 1b Single Dose Clinical Trial of a Novel Long-Acting Bispecific Antibody in People With HIV to Inform Development for HIV Pre- and Post-Exposure Prophylaxis

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibalizumab (Primary) ; Ibalizumab (Primary) ; TMB-380 (Primary) ; Antiretrovirals
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use

Most Recent Events

  • 25 Apr 2025 Planned End Date changed from 1 Feb 2026 to 1 May 2027.
  • 25 Apr 2025 Planned primary completion date changed from 1 May 2025 to 1 Apr 2026.
  • 25 Apr 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top